Recent Finacing
Recent Raise
Hillstar Bio develops precision immunology therapies that selectively deplete pathogenic TRBV9+ T cells, using tailored discovery, validated technologies, and disease-specific biomarkers to advance clinical studies in HLA-B27 conditions.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
